Drug Trial Radar · NCT06926491
Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study)
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
13
Actual
Start
Dec 1, 2024
Primary completion
May 31, 2029
Study completion May 31, 2031
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate the efficacy of KK8398 on annualized height velocity after 52 weeks of repeated administration of KK8398 to patients with achondroplasia
Conditions
- Achondroplasia
Interventions
KK8398Drug
KK8398 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in annualized height velocityTime frame: Pre-dose, Week 52
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Niigata University Medical and Dental Hospital
Niigata, Japan
Okayama University Hospital
Okayama, Japan
ISEIKAI International General Hospital
Osaka, Japan
Osaka City General Hospital
Osaka, Japan
Aichi Children's Health and Medical Center
Ōbu, Aichi-ken, Japan
Osaka University Hospital
Suita, Osaka, Japan
Osaka Women's and Children's Hospital
Waizumi, Osaka, Japan
Tokyo Metropolitan Children's Medical Center
Fuchū, Tokyo, Japan
Tottori University Hospital
Yonago, Tottori, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.